Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates and management. A neurobehavioral review

José A. Muñoz-Moreno; Carmina R. Fumaz; Maria J. Ferrer; Marian González-Garcia; José Moltó; Eugènia Negredo; Bonaventura Clotet

Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates and management. A neurobehavioral review

José A. Muñoz-Moreno, Carmina R. Fumaz, Maria J. Ferrer, Marian González-Garcia, José Moltó, Eugènia Negredo, Bonaventura Clotet

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

72 Citations (Scopus)

Abstract

The non-nucleoside analog reverse transcriptase inhibitor efavirenz is one of the most common components of HAART. Neuropsychiatric symptoms are frequently reported in patients taking efavirenzbased regimens. These symptoms are usually transient, although they can sometimes persist for up to two years after initiation of treatment. This review describes in detail the most common neuropsychiatric symptoms related to efavirenz, outlines relevant and recent findings on this agent, and suggests possible interventions based on neurobehavioral results. Different recommendations on the assessment of efavirenz-related adverse events are also provided.

Original language	English
Pages (from-to)	103-109
Journal	AIDS Reviews
Volume	11
Issue number	2
Publication status	Published - 15 Sept 2009

Keywords

Antiretroviral therapy
Efavirenz
HIV infection

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0ad0ae4e826b405983ea068acc82863f,

title = "Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates and management. A neurobehavioral review",

abstract = "The non-nucleoside analog reverse transcriptase inhibitor efavirenz is one of the most common components of HAART. Neuropsychiatric symptoms are frequently reported in patients taking efavirenzbased regimens. These symptoms are usually transient, although they can sometimes persist for up to two years after initiation of treatment. This review describes in detail the most common neuropsychiatric symptoms related to efavirenz, outlines relevant and recent findings on this agent, and suggests possible interventions based on neurobehavioral results. Different recommendations on the assessment of efavirenz-related adverse events are also provided.",

keywords = "Antiretroviral therapy, Efavirenz, HIV infection",

author = "Mu{\~n}oz-Moreno, {Jos{\'e} A.} and Fumaz, {Carmina R.} and Ferrer, {Maria J.} and Marian Gonz{\'a}lez-Garcia and Jos{\'e} Molt{\'o} and Eug{\`e}nia Negredo and Bonaventura Clotet",

year = "2009",

month = sep,

day = "15",

language = "English",

volume = "11",

pages = "103--109",

journal = "AIDS Reviews",

issn = "1139-6121",

number = "2",

}

TY - JOUR

T1 - Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates and management. A neurobehavioral review

AU - Muñoz-Moreno, José A.

AU - Fumaz, Carmina R.

AU - Ferrer, Maria J.

AU - González-Garcia, Marian

AU - Moltó, José

AU - Negredo, Eugènia

AU - Clotet, Bonaventura

PY - 2009/9/15

Y1 - 2009/9/15

N2 - The non-nucleoside analog reverse transcriptase inhibitor efavirenz is one of the most common components of HAART. Neuropsychiatric symptoms are frequently reported in patients taking efavirenzbased regimens. These symptoms are usually transient, although they can sometimes persist for up to two years after initiation of treatment. This review describes in detail the most common neuropsychiatric symptoms related to efavirenz, outlines relevant and recent findings on this agent, and suggests possible interventions based on neurobehavioral results. Different recommendations on the assessment of efavirenz-related adverse events are also provided.

AB - The non-nucleoside analog reverse transcriptase inhibitor efavirenz is one of the most common components of HAART. Neuropsychiatric symptoms are frequently reported in patients taking efavirenzbased regimens. These symptoms are usually transient, although they can sometimes persist for up to two years after initiation of treatment. This review describes in detail the most common neuropsychiatric symptoms related to efavirenz, outlines relevant and recent findings on this agent, and suggests possible interventions based on neurobehavioral results. Different recommendations on the assessment of efavirenz-related adverse events are also provided.

KW - Antiretroviral therapy

KW - Efavirenz

KW - HIV infection

M3 - Review article

SN - 1139-6121

VL - 11

SP - 103

EP - 109

JO - AIDS Reviews

JF - AIDS Reviews

IS - 2

ER -

Neuropsychiatric symptoms associated with efavirenz: Prevalence, correlates and management. A neurobehavioral review

Abstract

Keywords

UN SDGs

Fingerprint

Cite this